Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageZymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q1 2026 · $2.2MThe company’s own SEC segment disclosure.
- Royalty$1.3M61%
- Research Support Payments And Other Service$392.0K18%
- Drug Supply For Ongoing Studies$345.0K16%
- Drug Supply$117.0K5%
Zymeworks Inc. (ZYME) reported revenue of $2.4M in Q1 2026 (quarter ended March 31, 2026), down 91% from the same quarter a year earlier. That came with net loss of $44M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in 2026-Q1 was Royalty at $1.3M, 61% of the disclosed total, just ahead of Research Support Payments And Other Service at 18%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.